Search

Your search keyword '"Mucciarini C"' showing total 119 results
Start Over Author "Mucciarini C"
119 results on '"Mucciarini C"'

1. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Baruzzi, A., Albani, F., Calbucci, F., D'Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A.M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall'Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall'Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A.R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M.R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E.M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., Franceschi, Enrico, Tosoni, Alicia, Minichillo, Santino, Depenni, Roberta, Paccapelo, Alexandro, Bartolini, Stefania, Michiara, Maria, Pavesi, Giacomo, Urbini, Benedetta, Crisi, Girolamo, Cavallo, Michele A., Tosatto, Luigino, Dazzi, Claudio, Biasini, Claudia, Pasini, Giuseppe, Balestrini, Damiano, Zanelli, Francesca, Ramponi, Vania, Fioravanti, Antonio, Giombelli, Ermanno, De Biase, Dario, Baruzzi, Agostino, and Brandes, Alba A.

Published
2018
Full Text
View/download PDF

2. Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy

Author

Baldin, Elisa, Testoni, Stefania, de Pasqua, Silvia, Ferro, Salvatore, Albani, Fiorenzo, Baruzzi, Agostino, D’Alessandro, Roberto, Baruzzi, A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Cavallo, M., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A. M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Faedi, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Fallica, E., Granieri, E., Latini, F., Lelli, G., Monetti, C., Saletti, A., Schivalocchi, R., Seraceni, S., Tola, M. R., Urbini, B., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., and On behalf of PERNO study group

Published
2017
Full Text
View/download PDF

3. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

Author

Franceschi, Enrico, Depenni, Roberta, Paccapelo, Alexandro, Ermani, Mario, Faedi, Marina, Sturiale, Carmelo, Michiara, Maria, Servadei, Franco, Pavesi, Giacomo, Urbini, Benedetta, Pisanello, Anna, Crisi, Girolamo, Cavallo, Michele A., Dazzi, Claudio, Biasini, Claudia, Bertolini, Federica, Mucciarini, Claudia, Pasini, Giuseppe, Baruzzi, Agostino, Brandes, Alba A., Baruzzi, A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Cavallo, M., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A. M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., PastoreTrossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., and The PERNO Study Group

Published
2017
Full Text
View/download PDF

6. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

Author

Pilotto, S, Rossi, A, Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Spitaleri, G, Bria, E, Novello, S, Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S., Pilotto, S, Rossi, A, Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Spitaleri, G, Bria, E, Novello, S, Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, and Novello S.

Abstract

Non-small-cell lung cancer harboring uncommon epidermal growth factor receptor (EGFR) mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) presents a variable sensitivity to EGFR-tyrosine kinase inhibitors. With the final aim to enrich knowledge about uncommon EGFR mutations, we performed a post hoc analysis of the beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) trial. Thirty-five patients were included of the original 312 EGFR-mutated cases. The results of our analysis support the existence of a strong heterogeneity within patients harboring uncommon EGFR mutations, which implies the necessity to stratify the subgroups of rare mutations in individual entities with different clinical perspectives. Background: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study. Patients and Methods: Data of advanced NSCLC patients with uncommon EGFR mutations who received first-line first-generation EGFR-TKIs in 24 Italian Hospitals were collected. In this analysis we aimed to evaluate overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of EGFR-TKIs in NSCLC patients harboring uncommon EGFR mutations. Results: Thirty-five patients harboring uncommon EGFR mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) were included of the original 312 EGFR-mutated cases. Most of them

Published
2018

7. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Author

Pressiani, T., Boni, C., Rimassa, L., Labianca, R., Fagiuoli, S., Salvagni, S., Ferrari, D., Cortesi, E., Porta, C., Mucciarini, C., Latini, L., Carnaghi, C., Banzi, M., Fanello, S., De Giorgio, M., Lutman, F. R., Torzilli, G., Tommasini, M. A., Ceriani, R., Covini, G., Tronconi, M. C., Giordano, L., Locopo, N., Naimo, S., and Santoro, A.

Published
2013
Full Text
View/download PDF

8. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Author

Caffo, O., primary, Zagonel, V., additional, Baldessari, C., additional, Berruti, A., additional, Bortolus, R., additional, Buti, S., additional, Ceresoli, G.L., additional, Donini, M., additional, Ermacora, P., additional, Fornarini, G., additional, Fratino, L., additional, Masini, C., additional, Massari, F., additional, Mosca, A., additional, Mucciarini, C., additional, Procopio, G., additional, Tucci, M., additional, Verri, E., additional, Zucali, P., additional, and Buttigliero, C., additional

Published
2020
Full Text
View/download PDF

9. 739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)

Author

Stellato, M., primary, Santini, D., additional, Verzoni, E., additional, De Giorgi, U., additional, Casadei, C., additional, Buti, S., additional, Maruzzo, M., additional, Murianni, V., additional, Sbrana, A., additional, Di Lorenzo, G., additional, Anesi, C., additional, Sorarù, M., additional, Naglieri, E., additional, De Vivo, R., additional, Vignani, F., additional, Grillone, F., additional, Mucciarini, C., additional, Roviello, G., additional, Pignata, S., additional, and Procopio, G., additional

Published
2020
Full Text
View/download PDF

11. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study

Author

Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Bria, E, Spitaleri, G, Rossi, A, Novello, S, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S., Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Bria, E, Spitaleri, G, Rossi, A, Novello, S, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, and Novello S.

Abstract

Objectives: Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9-12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-line treatment choice. Materials and methods: From June 2009 until May 2013 patients affected by advanced NSCLC harbouring EGFR mutations receiving first-line TKI were collected mainly retrospectively in 24 Italian Centers. Primary objective was to describe the percentage of EGFR mutated patients receiving second-line therapy after progression to first-line EGFR-TKIs assessing the type, the activity in terms of objective response rate (ORR), efficacy in terms of progression free survival (PFS) and overall survival (OS), and safety of second-line treatment. Secondary objective was to describe the efficacy of first-line EGFR-TKIs. Results: 312 patients were included. Most of them were females (203, 65.1%), never smokers (200, 64.1%), with adenocarcinoma histology (290, 92.9%). The most common mutations were EGFR exon 19 deletion and L858R, detected in 186 and 97 cases (59.6% and 31.1%), respectively. At data cut-off, 274 patients (95.1%) received any second-line treatment (including best supportive care or local treatments only). A total of 163 patients received second-line systemic therapy with an ORR of 20.9% (95% CI:14.62-27.10), a median PFS and OS of 4.7 (95% CI:3.81-5.26) and 24.5 (95% CI:21.65-27.37) months, respectively. Grade 3-4 hematological and non-hematological toxicities were reported in 9% and 6.3% of 144 patients treated with chemotherapy while non-hematological toxicity was reported in 4 cases of the 17 patients receiving second-line target agents. Conclusions: BE-Positive is the first multicenter observational study reporting outcomes of therapies in a "real-life Caucasian EGFR-mutated population", highlighting the need of further researches about new treatment strategies in this setting.

Published
2016

12. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)

Author

Franceschi, Enrico, Depenni, Roberta, Paccapelo, Alexandro, Ermani, Mario, Faedi, Marina, Sturiale, Carmelo, Michiara, Maria, Servadei, Franco, Pavesi, Giacomo, Urbini, Benedetta, Pisanello, Anna, Crisi, Girolamo, Cavallo, Michele A., Dazzi, Claudio, Biasini, Claudia, Bertolini, Federica, Mucciarini, Claudia, Pasini, Giuseppe, Baruzzi, Agostino, Brandes, Alba A., Baruzzi, A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Cavallo, Marino, Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, Enrico, Biasini, C., Cavanna, L., Guidetti, D., Marcello, Norina, Pisanello, A., Cremonini, A. M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, Stefano, Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, Vincenzo, Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, Giuseppe, Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, Mario, Pasquini, Elena, Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, Greta, Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, Corrado, Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, Margherita, Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Cancer Research, Oncology, Neurology, Neurology (clinical)
Published
2018

13. Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Author

Caffo, O., primary, Palesandro, E., additional, Nole, F., additional, Gasparro, D., additional, Mucciarini, C., additional, Aieta, M., additional, Zagonel, V., additional, Iacovelli, R., additional, De Giorgi, U.F.F., additional, Rossetti, S., additional, Fratino, L., additional, Ermacora, P., additional, Nicodemo, M., additional, Giordano, M., additional, Sartori, D., additional, Scapoli, D., additional, Verri, E., additional, Maines, F., additional, Pappagallo, G., additional, and Aglietta, M., additional

Published
2019
Full Text
View/download PDF

14. First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., primary, Ciammella, P., additional, Timon, G., additional, Gnoni, R., additional, De Giorgi, U.F.F., additional, Bellia, S.R., additional, Buti, S., additional, Salaroli, F., additional, Milella, M., additional, Mazzarotto, R., additional, Mucciarini, C., additional, Vitale, M.G., additional, Bruni, A., additional, Procopio, G., additional, Kinspergher, S., additional, Nole, F., additional, Morelli, F., additional, Pappagallo, G., additional, buttigliero, C., additional, and Pinto, C., additional

Published
2019
Full Text
View/download PDF

15. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

Author

Franceschi, Enrico, Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A, Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Franceschi, E., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A. M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A. R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, Stefano, Nichelli, Paolo Frigio, Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., Franceschi, E., Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A.M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A.R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M.R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E.M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Oncology, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Dacarbazine, Population, Context (language use), NO, 03 medical and health sciences, 0302 clinical medicine, Elderly, Internal medicine, medicine, Temozolomide, Humans, MGMT methylation, Prospective Studies, Prospective cohort study, education, Promoter Regions, Genetic, Antineoplastic Agents, Alkylating, DNA Modification Methylases, Survival analysis, Aged, Aged, 80 and over, education.field_of_study, Radiotherapy, business.industry, Brain Neoplasms, Tumor Suppressor Proteins, Glioblastoma, Neurology (clinical), Neurology, DNA Methylation, Survival Analysis, Surgery, Radiation therapy, DNA Repair Enzymes, 030220 oncology & carcinogenesis, Concomitant, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

Published
2016

16. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Author

Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, Schinzari Giovanni (ORCID:0000-0001-6105-7252), Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, and Schinzari Giovanni (ORCID:0000-0001-6105-7252)

Abstract

AIM: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. METHODS: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. RESULTS: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001. CONCLUSION: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.

Published
2018

18. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging [J Neurooncol (2015) 123, 93-102, DOI 10.1007/s11060-015-1766-5]

Author

Yeung T. P. C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T. -Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A. M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A. R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M. R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E. M., Torelli P., Immovilli P., Morelli N., Vanzo C., Nobile C., Yeung T.P.C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T.-Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A.M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A.R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M.R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E.M., Torelli P., Immovilli P., Morelli N., Vanzo C., and Nobile C.

Subjects
PERNO, Gender, Glioblastoma, MGMT, Methylation
Abstract

Background: Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. Methods: We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. Results: A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242-0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002-1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948-0.982; P < 0.001) were significantly correlated with survival. Conclusions: Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.

Published
2015

19. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Franceschi, Enrico, primary, Tosoni, Alicia, additional, Minichillo, Santino, additional, Depenni, Roberta, additional, Paccapelo, Alexandro, additional, Bartolini, Stefania, additional, Michiara, Maria, additional, Pavesi, Giacomo, additional, Urbini, Benedetta, additional, Crisi, Girolamo, additional, Cavallo, Michele A., additional, Tosatto, Luigino, additional, Dazzi, Claudio, additional, Biasini, Claudia, additional, Pasini, Giuseppe, additional, Balestrini, Damiano, additional, Zanelli, Francesca, additional, Ramponi, Vania, additional, Fioravanti, Antonio, additional, Giombelli, Ermanno, additional, De Biase, Dario, additional, Baruzzi, Agostino, additional, Brandes, Alba A., additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Poggi, R., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Dall'Agata, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Faedi, M., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, A.R., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Ragazzi, M., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Colella, M., additional, Fallica, E., additional, Farneti, M., additional, Frassoldati, A., additional, Granieri, E., additional, Latini, F., additional, Monetti, C., additional, Saletti, A., additional, Schivalocchi, R., additional, Sarubbo, S., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Zini, G., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Giombelli, E., additional, Mazza, S., additional, Ramponi, V., additional, Servadei, F., additional, Silini, E.M., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, Vanzo, C., additional, and Nobile, C., additional

Published
2018
Full Text
View/download PDF

20. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Author

Pressiani, T, Boni, C, Rimassa, L, Labianca, R, Fagiuoli, S, Salvagni, S, Ferrari, D, Cortesi, E, Porta, C, Mucciarini, C, Latini, L, Carnaghi, C, Banzi, M, Fanello, S, De Giorgio, M, Lutman, F, Torzilli, G, Tommasini, M, Ceriani, R, Covini, G, Tronconi, M, Giordano, L, Locopo, N, Naimo, S, Santoro, A, Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A., Pressiani, T, Boni, C, Rimassa, L, Labianca, R, Fagiuoli, S, Salvagni, S, Ferrari, D, Cortesi, E, Porta, C, Mucciarini, C, Latini, L, Carnaghi, C, Banzi, M, Fanello, S, De Giorgio, M, Lutman, F, Torzilli, G, Tommasini, M, Ceriani, R, Covini, G, Tronconi, M, Giordano, L, Locopo, N, Naimo, S, Santoro, A, Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, and Santoro A.

Abstract

Background: Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B. Patients and methods: A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.]. Results: Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar. Conclusion: Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.

Published
2013

21. CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Author

Masini, C., primary, Vitale, M.G., additional, Maruzzo, M., additional, Procopio, G., additional, De Giorgi, U., additional, Buti, S., additional, Rossetti, S., additional, Iacovelli, R., additional, Guida, A., additional, Atzori, F., additional, Mucciarini, C., additional, Cosmai, L., additional, Vignani, F., additional, Prati, G., additional, Scagliarini, S., additional, Berselli, A., additional, and Pinto, C., additional

Published
2017
Full Text
View/download PDF

22. Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial

Author

Ruzzo, A., primary, Galli, F., additional, Rulli, E., additional, Lonardi, S., additional, Zagonel, V., additional, Ronzoni, M., additional, Ionta, M.T., additional, Pella, N., additional, Mucciarini, C., additional, Labianca, R., additional, Veltri, E., additional, Sozzi, P., additional, Barni, S., additional, Nicolini, M., additional, Biondi, E., additional, Bramati, A., additional, Turci, D., additional, Buscaglia, M., additional, Magnani, M., additional, and Graziano, F., additional

Published
2017
Full Text
View/download PDF

23. Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)

Author

Bracarda, S., primary, Galli, L., additional, Maruzzo, M., additional, Lo Re, G., additional, Buti, S., additional, Favaretto, A., additional, Costanzo, F.D., additional, Sacco, C., additional, Merlano, M., additional, Mucciarini, C., additional, Zafarana, E., additional, Romito, S., additional, Maestri, A., additional, Giannitto Giorgio, C., additional, Ionta, M.T., additional, Turci, D., additional, De Giorgi, U., additional, Procopio, G., additional, Cortesi, E., additional, and Porta, C., additional

Published
2017
Full Text
View/download PDF

24. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

Author

Ruzzo, A, primary, Graziano, F, additional, Galli, Fabio, additional, Galli, Francesca, additional, Rulli, E, additional, Lonardi, S, additional, Ronzoni, M, additional, Massidda, B, additional, Zagonel, V, additional, Pella, N, additional, Mucciarini, C, additional, Labianca, R, additional, Ionta, M T, additional, Bagaloni, I, additional, Veltri, E, additional, Sozzi, P, additional, Barni, S, additional, Ricci, V, additional, Foltran, L, additional, Nicolini, M, additional, Biondi, E, additional, Bramati, A, additional, Turci, D, additional, Lazzarelli, S, additional, Verusio, C, additional, Bergamo, F, additional, Sobrero, A, additional, Frontini, L, additional, Menghi, M, additional, and Magnani, M, additional

Published
2017
Full Text
View/download PDF

25. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Author

Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E., Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, and Zanon E.

Abstract

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

Published
2011

26. 961P - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., Ciammella, P., Timon, G., Gnoni, R., De Giorgi, U.F.F., Bellia, S.R., Buti, S., Salaroli, F., Milella, M., Mazzarotto, R., Mucciarini, C., Vitale, M.G., Bruni, A., Procopio, G., Kinspergher, S., Nole, F., Morelli, F., Pappagallo, G., buttigliero, C., and Pinto, C.

Published
2019
Full Text
View/download PDF

27. 854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Author

Caffo, O., Palesandro, E., Nole, F., Gasparro, D., Mucciarini, C., Aieta, M., Zagonel, V., Iacovelli, R., De Giorgi, U.F.F., Rossetti, S., Fratino, L., Ermacora, P., Nicodemo, M., Giordano, M., Sartori, D., Scapoli, D., Verri, E., Maines, F., Pappagallo, G., and Aglietta, M.

Published
2019
Full Text
View/download PDF

28. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III

Author

Visani, M, de Biase, D, Marucci, G, Cerasoli, S, Nigrisoli, E, Bacchi Reggiani ML, Albani, F, Baruzzi, A, Pession, A, Calbucci, F, D'Alessandro, R, Michelucci, R, Brandes, A, Eusebi, V, Ceruti, S, Fainardi, E, Tamarozzi, R, Emiliani, E, Cavallo, M, Franceschi, E, Tosoni, A, Fiorica, F, Valentini, A, Depenni, R, Mucciarini, C, Crisi, G, Sasso, E, Biasini, C, Cavanna, L, Guidetti, D, Marcello, N, Pisanello, A, Cremonini, Am, Guiducci, G, Agati, R, Ambrosetto, G, Bacci, A, Baldin, E, Baldrati, A, Barbieri, E, Bartolini, S, Bellavista, E, Bisulli, F, Bonora, E, Bunkheila, F, Carelli, V, Crisci, M, Dall'Occa, P, Ferro, S, Franceschi, C, Frezza, G, Grasso, V, Leonardi, M, Morandi, L, Mostacci, B, Palandri, G, Pasini, E, Pastore Trossello, M, Poggi, R, Riguzzi, P, Rinaldi, R, Rizzi, S, Romeo, G, Spagnolli, F, Tinuper, P, Trocino, C, Dall'Agata, M, Frattarelli, M, Gentili, G, Giovannini, A, Iorio, P, Pasquini, U, Galletti, G, Guidi, C, Neri, W, Patuelli, A, Strumia, S, Faedi, M, Casmiro, M, Gamboni, A, Rasi, F, Cruciani, G, Cenni, P, Dazzi, C, Guidi, Ar, Zumaglini, F, Amadori, A, Pasini, G, Pasquinelli, M, Pasquini, E, Polselli, A, Ravasio, A, Viti, B, Sintini, M, Ariatti, A, Bertolini, F, Bigliardi, G, Carpeggiani, P, Cavalleri, F, Meletti, S, Nichelli, P, Pettorelli, E, Pinna, G, Zunarelli, E, Artioli, F, Bernardini, I, Costa, M, Greco, G, Guerzoni, R, Stucchi, C, Iaccarino, C, Ragazzi, M, Rizzi, R, Zuccoli, G, Api, P, Cartei, F, Fallica, E, Granieri, E, Latini, F, Lelli, G, Monetti, C, Saletti, A, Schivalocchi, R, Seraceni, S, Tola, Mr, Urbini, B, Giorgi, C, Montanari, E, Cerasti, D, Crafa, P, Dascola, I, Florindo, I, Giombelli, E, Mazza, S, Ramponi, V, Servadei, F, Silini, Em, Torelli, P, Immovilli, P, Morelli, N, Vanzo, C, Nobile, C, Michela Visani, Dario de Biase, Gianluca Marucci, Serenella Cerasoli, Evandro Nigrisoli, Maria Letizia Bacchi Reggiani, Fiorenzo Albani, Agostino Baruzzi, Annalisa Pession, the PERNO study group [, Elena Bonora, and ]

Subjects
Adult, Male, Cancer Research, Low-grade brain tumor, Brain neoplasia, Glioblastoma, Low-grade brain tumors, MicroRNA, Real-time PCR, Aged, Brain Neoplasms, Female, Gene Expression Profiling, Humans, MicroRNAs, Middle Aged, Neoplasm Grading, RNA, Neoplasm, Gene Expression Regulation, Neoplastic, Genetics, Molecular Medicine, Biology, Bioinformatics, medicine.disease_cause, NO, Brain Neoplasm, Genetic, microRNA, medicine, Locked nucleic acid, MicroRNA, Glioblastoma, Brain neoplasia, Low-grade brain tumors, Real-time PCR, Cancer, General Medicine, medicine.disease, Molecular medicine, Fold change, Gene expression profiling, Real-time polymerase chain reaction, Oncology, Cancer research, Carcinogenesis, Corrigendum, Human
Abstract

Several biomarkers have been proposed as useful parameters to better specify the prognosis or to delineate new target therapy strategies for glioblastoma patients. MicroRNAs could represent putative target molecules, considering their role in tumorigenesis, cancer progression and their specific tissue expression. Although several studies have tried to identify microRNA signature for glioblastoma, a microRNA profile is still far from being well-defined. In this work the expression of 19 microRNAs (miR-7, miR-9, miR-9∗, miR-10a, miR-10b, miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330, miR-519d) was evaluated in sixty formalin-fixed and paraffin-embedded glioblastoma samples using a locked nucleic acid real-time PCR. Moreover, a comparison of miRNA expressions was performed between primary brain neoplasias of different grades (grades IV-I). The analysis of 14 validated miRNA expression in the 60 glioblastomas, using three different non-neoplastic references as controls, revealed a putative miRNA signature: mir-10b and miR-21 were up-regulated, while miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330 were down-regulated in glioblastomas. Comparing miRNA expression between glioblastoma group and gliomas of grades I-III, 3 miRNAs (miR-10b, mir-34a and miR-101) showed different regulation statuses between high-grade and low-grade tumors. miR-10b was up-regulated in high grade and significantly down-regulated in low-grade gliomas, suggesting that could be a candidate for a GBM target therapy. This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs.

Published
2014

29. Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial

Author

Graziano, F., primary, Ruzzo, A., additional, Rulli, E., additional, Galli, F., additional, Menghi, M., additional, Viti, D., additional, Giacomini, E., additional, Lonardi, S., additional, Ronzoni, M., additional, Massidda, B., additional, Pella, N., additional, Mucciarini, C., additional, Labianca, R., additional, Veltri, E., additional, Sozzi, P., additional, Barni, S., additional, Sobrero, A., additional, Frontini, L., additional, and Magnani, M., additional

Published
2016
Full Text
View/download PDF

30. Definition of miRNAs Expression Profile in Glioblastoma Samples: The Relevance of Non-Neoplastic Brain Reference

Author

Visani, Michela, De Biase, Dario, Marucci, Gianluca, Taccioli, Cristian, Baruzzi, Agostino, Pession, Annalisa, Baruzzi, A., Albani, F., Calbucci, F., D'alessandro, R., Michelucci, R., Brandes, A., Eusebieusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A. M., Guiducci, G., De Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall'occa, P., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Cerasoli, S., Dall'agata, M., Faedi, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Fallica, E., Granieri, E., Latini, F., Lelli, G., Monetti, C., Saletti, A., Schivalocchi, R., Seraceni, S., Tola, M. R., Urbini, B., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., M. Visani, D. de Biase, G. Marucci, C. Taccioli, A. Baruzzi, A. Pession, Perno Study Group, F. Albani, V. Eusebi, F. Bisulli, V. Carelli, M. Leonardi, B. Mostacci, P. Tinuper, the PERNO Study group [, E. Bonora, and ]

Subjects
Male, Genetics and Molecular Biology (all), Adult, Aged, Brain, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Glioblastoma, Humans, MicroRNAs, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistics, Nonparametric, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), Gene Expression, Bioinformatics, Biochemistry, Surgical oncology, Nucleic Acids, metabolism, Female, Gene Expression Profiling, Molecular Cell Biology, Basic Cancer Research, Gene expression, normal adjacent the tumor, Neurological Tumors, methods, Gene Expression Regulation, brain tumors, glioblastoma, miRNAs, Multidisciplinary, Cancer Risk Factors, Medicine (all), Statistics, non-neoplastic brain, Real-time polymerase chain reaction, Oncology, miRNAs, Medicine, DNA microarray, brain RNA commercial reference, Research Article, Adult, Aged, Brain, Neoplastic, genetics/physiology, Glioblastoma, metabolism, Humans, Male, MicroRNAs, metabolism, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistics, Nonparametric, Science, Brain tumor, Biology, NO, Molecular Genetics, epileptic tissue, Text mining, microRNA, medicine, miRNA, business.industry, Computational Biology, Cancers and Neoplasms, medicine.disease, Gene expression profiling, Gene Expression Regulation, Cancer research, RNA, brain tumors, metabolism, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistic, business, metabolism, Humans, Male, MicroRNA, Glioblastoma Multiforme
Abstract

Glioblastoma is the most aggressive brain tumor that may occur in adults. Regardless of the huge improvements in surgery and molecular therapy, the outcome of neoplasia remains poor. MicroRNAs are small molecules involved in several cellular processes, and their expression is altered in the vast majority of tumors. Several studies reported the expression of different miRNAs in glioblastoma, but one of the most critical point in understanding glioblastoma miRNAs profile is the comparison of these studies. In this paper, we focused our attention on the non-neoplastic references used for determining miRNAs expression. The aim of this study was to investigate if using three different non-neoplastic brain references (normal adjacent the tumor, commercial total RNA, and epileptic specimens) could provide discrepant results. The analysis of 19 miRNAs was performed using Real-Time PCR, starting from the set of samples described above and the expression values compared. Moreover, the three different normal RNAs were used to determine the miRNAs profile in 30 glioblastomas. The data showed that different non-neoplastic controls could lead to different results and emphasize the importance of comparing miRNAs profiles obtained using the same experimental condition.

Published
2013

34. P-283 Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial

Author

Passardi, A., primary, Scarpi, E., additional, Fontana, A., additional, Cavanna, L., additional, Ruscelli, S., additional, Turci, D., additional, Lorusso, V., additional, Mucciarini, C., additional, Tassinari, D., additional, Ragazzini, A., additional, Valgiusti, M., additional, Ulivi, P., additional, Frassineti, G.L., additional, and Amadori, D., additional

Published
2015
Full Text
View/download PDF

36. A3 - Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial

Author

Ruzzo, A., Galli, F., Rulli, E., Lonardi, S., Zagonel, V., Ronzoni, M., Ionta, M.T., Pella, N., Mucciarini, C., Labianca, R., Veltri, E., Sozzi, P., Barni, S., Nicolini, M., Biondi, E., Bramati, A., Turci, D., Buscaglia, M., Magnani, M., and Graziano, F.

Published
2017
Full Text
View/download PDF

38. 887P - Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)

Author

Bracarda, S., Galli, L., Maruzzo, M., Lo Re, G., Buti, S., Favaretto, A., Costanzo, F.D., Sacco, C., Merlano, M., Mucciarini, C., Zafarana, E., Romito, S., Maestri, A., Giannitto Giorgio, C., Ionta, M.T., Turci, D., De Giorgi, U., Procopio, G., Cortesi, E., and Porta, C.

Published
2017
Full Text
View/download PDF

39. Metastatic Renal Cell Carcinoma (Mrcc) Treated with Targeted Therapies (Tt) in the Community Setting: an Italian Survey on 1238 Pts

Author

Pasini, F., primary, Fraccon, A.P., additional, Zustovich, F., additional, Sacco, C., additional, Valcamonico, F., additional, Donati, D., additional, Durante, E., additional, Sorarù, M., additional, Nicodemo, M., additional, Cengarle, R., additional, Randisi, P., additional, Ogliosi, C., additional, Bernardi, D., additional, Ciccarese, C., additional, Zanon, S., additional, Martellucci, I., additional, Falco, I., additional, Mucciarini, C., additional, Mandarà, M., additional, and Santabarbara, G., additional

Published
2014
Full Text
View/download PDF

40. Body Mass Index and Bevacizumab-Based Therapy in Advanced Colorectal Cancer Patients: Evaluation of Clinical Outcome

Author

Farolfi, A., primary, Scarpi, E., additional, Passardi, A., additional, Tassinari, D., additional, Tamberi, S., additional, Cavanna, L., additional, Fontana, A., additional, Mucciarini, C., additional, Vertogen, B., additional, Valgiusti, M., additional, Gardini, A. Casadei, additional, Valtancoli, M., additional, Pini, S., additional, and Frassineti, G.L., additional

Published
2014
Full Text
View/download PDF

42. Pharmacogenetic Profiling for Toxicity of Oxaliplatin and Fluoropyrimidines. Final Report from an Ancillary Protocol to the Tosca (Three or Six Colon Adjuvant) Trial

Author

Graziano, F., primary, Ruzzo, A., additional, Galli, F., additional, Giacomini, E., additional, Floriani, I.C., additional, Rulli, E., additional, Lonardi, S., additional, Ronzoni, M., additional, Massidda, B., additional, Zagonel, V., additional, Pella, N., additional, Mucciarini, C., additional, Labianca, R., additional, Veltri, E., additional, Sozzi, P., additional, Barni, S., additional, Ricci, V., additional, Sobrero, A., additional, and Magnani, M., additional

Published
2014
Full Text
View/download PDF

43. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

Author

Brandes, Alba A., primary, Franceschi, Enrico, additional, Ermani, Mario, additional, Tosoni, Alicia, additional, Albani, Fiorenzo, additional, Depenni, Roberta, additional, Faedi, Marina, additional, Pisanello, Anna, additional, Crisi, Girolamo, additional, Urbini, Benedetta, additional, Dazzi, Claudio, additional, Cavanna, Luigi, additional, Mucciarini, Claudia, additional, Pasini, Giuseppe, additional, Bartolini, Stefania, additional, Marucci, Gianluca, additional, Morandi, Luca, additional, Zunarelli, Elena, additional, Cerasoli, Serenella, additional, Gardini, Giorgio, additional, Lanza, Giovanni, additional, Silini, Enrico Maria, additional, Cavuto, Silvio, additional, Baruzzi, Agostino, additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Mazzocchi, V., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Ragazzi, M., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Cerasoli, S., additional, Dall'Agata, M., additional, Faedi, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, AR., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Fallica, E., additional, Granieri, E., additional, Latini, F., additional, Lelli, G., additional, Monetti, C., additional, Ramponi, V., additional, Saletti, A., additional, Schivalocchi, R., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Mazza, S., additional, Servadei, F., additional, Silini, EM., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, and Vanzo, C., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results